In the evolving landscape of diabetes management, novel medications like semaglutide and retatrutide are gaining traction. These agents, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, offer promising benefits in controlling blood glucose levels. While both share a similar mechanism of action, they exhibit different pharmac

The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing variations in